Abstract Aims/Introduction Diabetes mellitus is an established risk factor for stroke and
maybe associated with poorer outcomes after stroke. The aims of the present literature …

Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Importance Hyperglycemia during acute ischemic stroke is common and is associated with
worse outcomes. The efficacy of intensive treatment of hyperglycemia in this setting remains …

Diabetes and ischaemic stroke often arise together. People with diabetes have more than
double the risk of ischaemic stroke after correction for other risk factors, relative to …

Background and Purpose—Symptomatic intracerebral hemorrhage (SICH) is a serious
complication in patients with acute ischemic stroke treated with intravenous thrombolysis …

Background and Purpose—The potential detrimental effect of diabetes mellitus and
admission glucose level (AGL) on outcomes after stroke thrombolysis is unclear. We …

Background Hemorrhagic transformation (HT) following reperfusion therapies for acute
ischaemic stroke often predicts a poor prognosis. This systematic review and meta-analysis …

Background and Purpose—Diabetes mellitus is an established risk factor for stroke.
However, it is uncertain whether prestroke glycemic control (PSGC) status affects clinical …

Background and Purpose: High-serum glucose on admission is a predictor of poor outcome
after stroke. We assessed the association between glucose concentrations and clinical …